{"trial_id":{"0":796,"1":784,"2":756,"3":748,"4":739,"5":736,"6":732,"7":731,"8":730,"9":729,"10":727,"11":726,"12":724,"13":723,"14":722,"15":721,"16":717,"17":715,"18":700,"19":697,"20":687,"21":667,"22":663,"23":659,"24":655,"25":650,"26":646,"27":642,"28":641,"29":640,"30":636,"31":634,"32":632,"33":602,"34":601,"35":600,"36":599,"37":587,"38":585,"39":582,"40":554,"41":553,"42":549,"43":543,"44":533,"45":511,"46":501,"47":494,"48":486,"49":485,"50":483,"51":482,"52":474,"53":459,"54":454,"55":333,"56":332,"57":330,"58":323,"59":322,"60":321,"61":320,"62":318,"63":317,"64":316,"65":315,"66":313,"67":312,"68":310,"69":309,"70":308,"71":305,"72":304,"73":295,"74":290,"75":289,"76":287,"77":268,"78":267,"79":266,"80":265,"81":264,"82":263,"83":262,"84":261,"85":260,"86":259,"87":258,"88":257,"89":256,"90":255,"91":254,"92":253,"93":252,"94":251,"95":250,"96":248,"97":245,"98":242,"99":234,"100":210,"101":206,"102":180,"103":179,"104":176,"105":173,"106":172,"107":170,"108":47,"109":9,"110":8,"111":7,"112":6,"113":5,"114":4,"115":3,"116":2},"discovery_date":{"0":1651070653394,"1":1651070653334,"2":1650910207659,"3":1650910206842,"4":1650910206813,"5":1650910206804,"6":1650817401899,"7":1650817401896,"8":1650817401893,"9":1650817401890,"10":1650817401878,"11":1650817401303,"12":1650817401299,"13":1650817401297,"14":1650817401293,"15":1650817401290,"16":1650817401283,"17":1650817401278,"18":1650801472324,"19":1650801472299,"20":1650801472242,"21":1650024774188,"22":1650024774178,"23":1650024774173,"24":1650024774166,"25":1650024774144,"26":1650024774129,"27":1650024774115,"28":1650024774115,"29":1650024774113,"30":1650024773644,"31":1650024773648,"32":1650024773646,"33":1650017556654,"34":1650017556651,"35":1650017556648,"36":1650017556645,"37":1649805767662,"38":1649805767657,"39":1649805766972,"40":1649607834540,"41":1649607834536,"42":1649607834528,"43":1649607834515,"44":1649607833912,"45":1649346442235,"46":1649346442221,"47":1649346441434,"48":1649193374466,"49":1649193374464,"50":1649193374461,"51":1649193374458,"52":1649193374422,"53":1649193374385,"54":1649193373762,"55":1648920616068,"56":1648920616067,"57":1648920616062,"58":1648920616047,"59":1648920616046,"60":1648920616045,"61":1648920616043,"62":1648920616037,"63":1648920616027,"64":1648920616025,"65":1648920616024,"66":1648920616022,"67":1648920616020,"68":1648920616008,"69":1648920616006,"70":1648920616004,"71":1648920615320,"72":1648920615315,"73":1648681069243,"74":1648681069221,"75":1648681069217,"76":1648681069206,"77":1648589308071,"78":1648589308064,"79":1648589308056,"80":1648589308044,"81":1648589308036,"82":1648589308028,"83":1648589308020,"84":1648589308014,"85":1648589308008,"86":1648589308001,"87":1648589307995,"88":1648589307990,"89":1648589307978,"90":1648589307972,"91":1648589307965,"92":1648589307957,"93":1648589307950,"94":1648589307944,"95":1648589307930,"96":1648589307478,"97":1648589307460,"98":1648589307434,"99":1648424677254,"100":1648056908068,"101":1648056908052,"102":1647798026695,"103":1647798026692,"104":1647798026686,"105":1647798026674,"106":1647798026671,"107":1647798025855,"108":1647104801941,"109":1646853978171,"110":1646853978166,"111":1646853978164,"112":1646853978161,"113":1646853978158,"114":1646853978156,"115":1646853978152,"116":1646853977110},"title":{"0":"CSF Free Kappa Light Chain for The Diagnosis of Demyelinating Disorders","1":"Metformin Treatment in Progressive Multiple Sclerosis","2":"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer\u2019s Disease ...","3":"Effect of Computerized Cognitive Training in Persons With MS","4":"Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial","5":"A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis","6":"A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...","7":"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)","8":"Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS)","9":"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio\u00ae) in participants with relapsing forms of multiple sclerosis","10":"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Onc...","11":"Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis","12":"Kinesiotape on Balance in With Multiple Sclerosis","13":"Study of Empathy in MS","14":"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia\u00ae)","15":"Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis","16":"Proprioceptive Neuromuscular Facilitation in Multiple Sclerosis","17":"A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA\u00ae Indicated for Multiple Sclerosis","18":"A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients \u226518 Years of Age","19":"Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced&#x2F;Recurrent Non-small Cell Lung Cancer)","20":"A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema","21":"A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria","22":"A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan","23":"A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension","24":"A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)","25":"Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)","26":"A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors","27":"A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration","28":"More locations","29":"Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer&#39;s Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory ...","30":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)","31":"","32":"An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)","33":"Functional Outcomes From Diets in Multiple Sclerosis","34":"Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis","35":"Defining an Immunological Signature Related to Lesion Location in Multiple Sclerosis","36":"L Test in Multiple Sclerosis","37":"TENS in Persons With MS","38":"Therapeutic Effects of Line Dancing in People With MS","39":"Immersive Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis","40":"Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)","41":"Phase III: UbliTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)","42":"A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...","43":"An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis","44":"Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients","45":"A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg\/kg\/day versus Placebo in the T...","46":"Post-authorization safety study to check the potential association between the safety\nprofile of beta interferon 1a and the body mass index or pharmacodynamics during the\ntitration phase","47":"Exercise and Pregnancy in People With Multiple Sclerosis","48":"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...","49":"The effect of Tecfidera\u00ae (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.","50":"A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...","51":"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis","52":"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (...","53":"Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis","54":"Multiple Sclerosis and Overactive Bladder Treatment","55":"A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX\u00ae (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respira...","56":"A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446\/ Placebo and a Single Dos...","57":"Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAM...","58":"A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis","59":"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)","60":"Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study","61":"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lu...","62":"An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...","63":"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis","64":"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300...","65":"A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis","66":"Multicenter, open-label, 12 weeks,\r\nphaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a\r\n(Rebif\u00ae) administered In the morning may affEct the severity of Flu-like syndrom...","67":"Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study","68":"A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects...","69":"Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T","70":"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.","71":"A Study for Tysabri Participant Preference","72":"Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials","73":"Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA\u00ae (efalizumab) in the framework of...","74":"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning fro...","75":"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis","76":"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUT...","77":"Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn\u2019s disease","78":"Ensayo de fase III, multic\u00e9ntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...","79":"A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS)","80":"An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT-physician\u2019s choi...","81":"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN...","82":"A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.","83":"Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.\nA cross-over, double-blinded, placebo-controlled study.","84":"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN\nPATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...","85":"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS","86":"Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis","87":"A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis","88":"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Scleros...","89":"Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously ...","90":"A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)","91":"A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followe...","92":"A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis","93":"Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri\u00ae in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)","94":"AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS","95":"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex\u00ae (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis","96":"Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study","97":"Gait Analysis in Multiple Sclerosis Patients","98":"Drug Repurposing for Improving the Therapeutic Outcome in Multiple Sclerosis Patients","99":"B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis","100":"An Assistive Powered Wheelchair: Stage 2 Trial","101":"Cellular microRNA Signatures in Multiple Sclerosis","102":"A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers","103":"Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients","104":"Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis","105":"Famciclovir in Multiple Sclerosis","106":"Kesimpta\u00ae (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study","107":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","108":"Neuromodulation in MS Using Translingual Stimulation","109":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","110":"Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf","111":"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","112":"Exploring Cortical Remyelination in Children With Multiple Sclerosis","113":"A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis","114":"Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)","115":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","116":"Function Magnetic Resonance Imaging to Assess Two Therapeutic Strategies in Multiple Sclerosis (NeuroRehEM)."},"summary":{"0":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Diagnostic\u00a0Test:\u00a0Kappa\u00a0Free\u00a0Light\u00a0Chain\u00a0(K-FLC)<br \/><b>Sponsor<\/b>: \u00a0  Aga\u00a0Khan\u00a0University<br \/><b>Completed<\/b>","1":"<b>Conditions<\/b>: \u00a0  Secondary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis; \u00a0 Primary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug: Metformin 500 Mg Oral Tablet, up to 4 tablets a day; \u00a0 Drug: Placebo oral tablet identical to metformin, up to 4 tablets a day<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0California,\u00a0Los\u00a0Angeles<br \/><b>Not yet recruiting<\/b>","2":"<p>EudraCT Number: 2017-002901-37<br \/>Sponsor Protocol Number: 251AD201<br \/>Sponsor Name: Biogen Idec Research Limited<br \/>Start Date: 2018-06-04<br \/>Medical condition: Mild cognitive impairment (MCI) due to Alzheimer\u2019s disease (AD) or mild AD<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 100000004852<br \/>Classification Code: 10001896<br \/>Term: Alzheimer's disease<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002901-37\/FR\">FR<\/a> (Prematurely Ended)<\/p>","3":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Interventions<\/b>: \u00a0  Device:\u00a0BrainHQ\u00a0cognitive\u00a0training; \u00a0 Device:\u00a0BrainHQ\u00a0control\u00a0games<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0Nebraska<br \/><b>Not yet recruiting<\/b>","4":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral: Remotely Delivered and Supported Aerobic Walking Exercise Training; \u00a0 Behavioral: Remotely Delivered and Supported Stretching and Toning Exercise Training<br \/><b>Sponsor<\/b>: \u00a0  Kessler\u00a0Foundation<br \/><b>Not yet recruiting<\/b>","5":"<b>Condition<\/b>: \u00a0  Relapsing\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0ofatumumab; \u00a0 Other:\u00a0glatiramer\u00a0acetate; \u00a0 Other:\u00a0interferon\u00a0\u03b21<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","6":"<p>EudraCT Number: 2013-003752-21<br \/>Sponsor Protocol Number: BN40898(SA-307JG)<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd.<br \/>Start Date: 2014-05-19<br \/>Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 100000004852<br \/>Classification Code: 10029322<br \/>Term: Neuromyelitis optica<br \/>Level: LLT<br \/><br \/>Population Age: Adolescents, Under 18, Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003752-21\/ES\">ES<\/a> (Ongoing)<\/p>","7":"<p>EudraCT Number: 2021-000028-36<br \/>Sponsor Protocol Number: P3-IMU-838-RMS-01<br \/>Sponsor Name: Immunic AG<br \/>Start Date: 2022-01-18<br \/>Medical condition: Relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000028-36\/BG\">BG<\/a> (Ongoing)<\/p>","8":"<p>EudraCT Number: 2021-000307-20<br \/>Sponsor Protocol Number: COMB157GDE01<br \/>Sponsor Name: Novartis Pharma Vertriebs GmbH <br \/>Start Date: 2021-04-28<br \/>Medical condition: relapsing multiple sclerosis <br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000307-20\/DE\">DE<\/a> (Ongoing)<\/p>","9":"<p>EudraCT Number: 2020-000637-41<br \/>Sponsor Protocol Number: EFC16033<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2020-07-31<br \/>Medical condition: Relapsing Multiple Sclerosis <br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/FI\">FI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/IT\">IT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000637-41\/RO\">RO<\/a> (Ongoing)<\/p>","10":"<p>EudraCT Number: 2011-005249-12<br \/>Sponsor Protocol Number: EFC11759<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2014-08-13<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 17.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Children, Adolescents, Under 18<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/EE\">EE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/GR\">GR<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/FR\">FR<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/LT\">LT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/3rd\">Outside EU\/EEA<\/a>, <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/IE\">IE<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/NL\">NL<\/a> (Restarted), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/SI\">SI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005249-12\/IT\">IT<\/a> (Not Authorised)<\/p>","11":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting; \u00a0 Adult\u00a0ALL; \u00a0 Vitamin\u00a0D3\u00a0Deficiency<br \/><b>Interventions<\/b>: \u00a0  Dietary\u00a0Supplement:\u00a025(OH)D3; \u00a0 Dietary\u00a0Supplement:\u00a0vitamin\u00a0D3<br \/><b>Sponsors<\/b>: \u00a0  Tehran\u00a0University\u00a0of\u00a0Medical\u00a0Sciences; \u00a0 Boston\u00a0University<br \/><b>Not yet recruiting<\/b>","12":"<b>Conditions<\/b>: \u00a0  Individuals\u00a0With\u00a0Multiple\u00a0Sclerosis; \u00a0 With\u00a0Ataxia\u00a0Symptoms; \u00a0 No\u00a0Secondary\u00a0Disease\u00a0Affecting\u00a0Balance<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Kinesiotape<br \/><b>Sponsor<\/b>: \u00a0  Firat\u00a0University<br \/><b>Recruiting<\/b>","13":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Interpersonal\u00a0Reactivity\u00a0Index<br \/><b>Sponsor<\/b>: \u00a0  Assistance\u00a0Publique\u00a0-\u00a0H\u00f4pitaux\u00a0de\u00a0Paris<br \/><b>Not yet recruiting<\/b>","14":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  <br \/><b>Sponsor<\/b>: \u00a0  Bristol-Myers\u00a0Squibb<br \/><b>Recruiting<\/b>","15":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Internuclear\u00a0Ophthalmoplegia<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Clemastine\u00a0Fumarate; \u00a0 Drug:\u00a0Placebo<br \/><b>Sponsor<\/b>: \u00a0  Amsterdam\u00a0UMC,\u00a0location\u00a0VUmc<br \/><b>Not yet recruiting<\/b>","16":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0PNF; \u00a0 Other:\u00a0Breathing\u00a0exercises<br \/><b>Sponsor<\/b>: \u00a0  Biruni\u00a0University<br \/><b>Not yet recruiting<\/b>","17":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Kesimpta<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Recruiting<\/b>","18":"","19":"","20":"","21":"","22":"","23":"","24":"","25":"","26":"","27":"","28":"","29":"","30":"","31":"","32":"","33":"<b>Conditions<\/b>: \u00a0  Relapsing\u00a0Remitting\u00a0Multiple\u00a0Sclerosis; \u00a0 Secondary\u00a0Progressive\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0Glycemic\u00a0load; \u00a0 Behavioral:\u00a0Calorie\u00a0restriction; \u00a0 Behavioral:\u00a0Behavioral\u00a0support<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Alabama\u00a0at\u00a0Birmingham; \u00a0 Washington\u00a0University\u00a0School\u00a0of\u00a0Medicine; \u00a0 United\u00a0States\u00a0Department\u00a0of\u00a0Defense<br \/><b>Not yet recruiting<\/b>","34":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Pain<br \/><b>Intervention<\/b>: \u00a0  Behavioral: Telerehabilitation-based motor imagery training<br \/><b>Sponsors<\/b>: \u00a0  Dokuz\u00a0Eylul\u00a0University; \u00a0 Izmir\u00a0Katip\u00a0Celebi\u00a0University<br \/><b>Not yet recruiting<\/b>","35":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0cytof\u00a0analysis<br \/><b>Sponsor<\/b>: \u00a0  Rennes\u00a0University\u00a0Hospital<br \/><b>Recruiting<\/b>","36":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Behavioral:\u00a0L\u00a0test<br \/><b>Sponsor<\/b>: \u00a0  Firat\u00a0University<br \/><b>Recruiting<\/b>","37":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Device: Trancutaneous Electrical Nerve Stimulation; \u00a0 Other:\u00a0Strength\u00a0training; \u00a0 Device:\u00a0Sham\u00a0stimulation<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0Medical\u00a0Center\u00a0Groningen<br \/><b>Not yet recruiting<\/b>","38":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0line\u00a0dancing<br \/><b>Sponsors<\/b>: \u00a0  Gazi\u00a0University; \u00a0 Hacettepe\u00a0University; \u00a0 Fenerbahce\u00a0University<br \/><b>Completed<\/b>","39":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Immersive\u00a0Virtual\u00a0Reality\u00a0Intervention<br \/><b>Sponsors<\/b>: \u00a0  Glasgow\u00a0Caledonian\u00a0University; \u00a0 MS\u00a0Society,\u00a0UK; \u00a0 NHS\u00a0Lanarkshire<br \/><b>Not yet recruiting<\/b>","40":"<p>EudraCT Number: 2017-000638-75<br \/>Sponsor Protocol Number: TG1101-RMS301<br \/>Sponsor Name: TG Therapeutics<br \/>Start Date: 2017-12-05<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029202<br \/>Term: Nervous system disorder<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000638-75\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000638-75\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000638-75\/ES\">ES<\/a> (Completed)<\/p>","41":"<p>EudraCT Number: 2017-000639-15<br \/>Sponsor Protocol Number: TG1101-RMS302<br \/>Sponsor Name: TG Therapeutics<br \/>Start Date: 2017-12-04<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029202<br \/>Term: Nervous system disorder<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000639-15\/HR\">HR<\/a> (Completed)<\/p>","42":"<p>EudraCT Number: 2018-000001-23<br \/>Sponsor Protocol Number: DroSpas-1<br \/>Sponsor Name: Bionorica SE <br \/>Start Date: 2018-10-25<br \/>Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029205<br \/>Term: Nervous system disorders<br \/>Level: SOC<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000001-23\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000001-23\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000001-23\/ES\">ES<\/a> (Completed)<\/p>","43":"<p>EudraCT Number: 2016-002937-31<br \/>Sponsor Protocol Number: MA30143<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2017-09-12<br \/>Medical condition: Relapsing remitting multiple sclerosis (RRMS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/NO\">NO<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/HR\">HR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002937-31\/IT\">IT<\/a> (Ongoing)<\/p>","44":"<b>Conditions<\/b>: \u00a0  Fatigue; \u00a0 Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Ozanimod<br \/><b>Sponsors<\/b>: \u00a0  Brigham\u00a0and\u00a0Women's\u00a0Hospital; \u00a0 Bristol-Myers\u00a0Squibb<br \/><b>Not yet recruiting<\/b>","45":"<p>EudraCT Number: 2021-000639-30<br \/>Sponsor Protocol Number: AB20009<br \/>Sponsor Name: AB Science<br \/>Start Date: 2022-01-12<br \/>Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063400<br \/>Term: Secondary progressive multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000639-30\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000639-30\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000639-30\/GR\">GR<\/a> (Ongoing)<\/p>","46":"<p>EudraCT Number: 2006-000606-23<br \/>Sponsor Protocol Number: 26756<br \/>Sponsor Name: Merck, S.L.<br \/>Start Date: 2006-11-23<br \/>Medical condition: Not applicalbe<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-000606-23\/ES\">ES<\/a> (Completed)<\/p>","47":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Pregnancy<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Moderate-intensity\u00a0cardiovascular\u00a0exercise<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0of\u00a0Alberta<br \/><b>Recruiting<\/b>","48":"<p>EudraCT Number: 2020-005929-89<br \/>Sponsor Protocol Number: CLOU064C12302<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2022-02-01<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005929-89\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005929-89\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005929-89\/SI\">SI<\/a> (Ongoing)<\/p>","49":"<p>EudraCT Number: 2015-001197-18<br \/>Sponsor Protocol Number: NOR-BGT-14-10665<br \/>Sponsor Name: Biogen Idec Norway<br \/>Start Date: 2015-05-20<br \/>Medical condition: multiple sclerosis<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-001197-18\/NO\">NO<\/a> (Completed)<\/p>","50":"<p>EudraCT Number: 2019-004822-15<br \/>Sponsor Protocol Number: GNC-401<br \/>Sponsor Name: GeNeuro Innovation SAS<br \/>Start Date: 2020-05-18<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004822-15\/SE\">SE<\/a> (Completed)<\/p>","51":"<p>EudraCT Number: 2021-000048-23<br \/>Sponsor Protocol Number: P2-IMU-838-PMS<br \/>Sponsor Name: Immunic AG<br \/>Start Date: 2021-10-28<br \/>Medical condition: Progressive forms of Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10053395<br \/>Term: Progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000048-23\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000048-23\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000048-23\/NL\">NL<\/a> (Ongoing)<\/p>","52":"<p>EudraCT Number: 2014-001579-30<br \/>Sponsor Protocol Number: TV5600-CNS-20006<br \/>Sponsor Name: Teva Pharmaceutical Industries Ltd.<br \/>Start Date: 2014-11-27<br \/>Medical condition: Primary Progressive Multiple Sclerosis<br \/>Disease: <br \/>Version: 19.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/IT\">IT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001579-30\/NL\">NL<\/a> (Completed)<\/p>","53":"<p>EudraCT Number: 2018-004557-24<br \/>Sponsor Protocol Number: UKM17_0056<br \/>Sponsor Name: Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster c\/o Universit\u00e4tsklinikum M\u00fcnster, Gesch\u00e4ftsbereich Recht u. Drittmittel <br \/>Start Date: 2019-07-29<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004557-24\/DE\">DE<\/a> (Temporarily Halted)<\/p>","54":"<b>Condition<\/b>: \u00a0  Neurogenic\u00a0Bladder\u00a0Dysfunction<br \/><b>Interventions<\/b>: \u00a0  Device: Repetitive Transcranial Magnetic Stimulation; \u00a0 Device: Transcutaneous Posterior Tibial Nerve Stimulation<br \/><b>Sponsor<\/b>: \u00a0  Istanbul\u00a0Medipol\u00a0University\u00a0Hospital<br \/><b>Enrolling by invitation<\/b>","55":"<p>EudraCT Number: 2006-006299-39<br \/>Sponsor Protocol Number: 191622-082-01<br \/>Sponsor Name: Allergan<br \/>Start Date: 2008-04-23<br \/>Medical condition: Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy ...<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10046543<br \/>Term: Urinary incontinence<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-006299-39\/NL\">NL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-006299-39\/FR\">FR<\/a> (Completed)<\/p>","56":"<p>EudraCT Number: 2010-018273-38<br \/>Sponsor Protocol Number: D1950C00011<br \/>Sponsor Name: AstraZeneca AB<br \/>Start Date: 2010-03-22<br \/>Medical condition: Alzheimer's Disease<br \/>Disease: <br \/>Version: 12.1<br \/>SOC Term: <br \/>Classification Code: 10001896<br \/>Term: Alzheimer's disease<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-018273-38\/FR\">FR<\/a> (Completed)<\/p>","57":"<p>EudraCT Number: 2009-011088-35<br \/>Sponsor Protocol Number: PACAMUS<br \/>Sponsor Name: Philipps-Universit\u00e4t Marburg<br \/>Start Date: 2010-03-24<br \/>Medical condition: Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP\/PACAP (vasoactive int...<br \/>Disease: <br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-011088-35\/DE\">DE<\/a> (Completed)<\/p>","58":"<p>EudraCT Number: 2011-001437-16<br \/>Sponsor Protocol Number: CFTY720D2319<br \/>Sponsor Name: Novartis Pharma Services AG<br \/>Start Date: 2012-09-19<br \/>Medical condition: multiple sclerosis<br \/>Disease: <br \/>Version: 15.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-001437-16\/DE\">DE<\/a> (Completed)<\/p>","59":"<p>EudraCT Number: 2020-000645-14<br \/>Sponsor Protocol Number: EFC16035<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2020-10-13<br \/>Medical condition: Primary Progressive Multiple Sclerosis <br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000645-14\/HR\">HR<\/a> (Ongoing)<\/p>","60":"<p>EudraCT Number: 2013-002113-35<br \/>Sponsor Protocol Number: MD1003CT2013-02MS-SPI<br \/>Sponsor Name: MEDDAY SAS<br \/>Start Date: Information not available in EudraCT<br \/>Medical condition: Progressive spinal multiple sclerosis<br \/>Disease: <br \/>Version: 18.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10053395<br \/>Term: Progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002113-35\/FR\">FR<\/a> (Completed)<\/p>","61":"<p>EudraCT Number: 2015-000392-28<br \/>Sponsor Protocol Number: 1199.214<br \/>Sponsor Name: Boehringer Ingelheim bv<br \/>Start Date: 2015-11-02<br \/>Medical condition: Patients with Systemic Sclerosis and associated Interstitial Lung Disease<br \/>Disease: <br \/>Version: 19.1<br \/>SOC Term: 100000004859<br \/>Classification Code: 10012977<br \/>Term: Diffuse systemic sclerosis<br \/>Level: LLT<br \/>Version: 19.1<br \/>SOC Term: 100000004859<br \/>Classification Code: 10036814<br \/>Term: Progressive systemic sclerosis<br \/>Level: LLT<br \/>Version: 19.1<br \/>SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br \/>Classification Code: 10042954<br \/>Term: Systemic sclerosis pulmonary<br \/>Level: PT<br \/>Version: 19.1<br \/>SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders<br \/>Classification Code: 10025109<br \/>Term: Lung involvement in systemic sclerosis<br \/>Level: LLT<br \/>Version: 19.1<br \/>SOC Term: 100000004859<br \/>Classification Code: 10042953<br \/>Term: Systemic sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/PT\">PT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/DK\">DK<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/GR\">GR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/FR\">FR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/IE\">IE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/FI\">FI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/NO\">NO<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/AT\">AT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/HU\">HU<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000392-28\/IT\">IT<\/a> (Completed)<\/p>","62":"<p>EudraCT Number: 2005-004061-41<br \/>Sponsor Protocol Number: 101-MS-321<br \/>Sponsor Name: BIOGEN IDEC LTD<br \/>Start Date: 2006-06-01<br \/>Medical condition: Multiple sclerosis (MS)<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/GB\">GB<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/BE\">BE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/FI\">FI<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/IE\">IE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/SE\">SE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/HU\">HU<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/DK\">DK<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/CZ\">CZ<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/IT\">IT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004061-41\/GR\">GR<\/a> (Completed)<\/p>","63":"<p>EudraCT Number: 2020-000647-30<br \/>Sponsor Protocol Number: EFC16645<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2020-08-27<br \/>Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063400<br \/>Term: Secondary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/FI\">FI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000647-30\/IT\">IT<\/a> (Ongoing)<\/p>","64":"<p>EudraCT Number: 2005-005985-35<br \/>Sponsor Protocol Number: 1206.15<br \/>Sponsor Name: Boehringer Ingelheim<br \/>Start Date: 2006-08-29<br \/>Medical condition: Relapsing forms of Multiple Sclerosis<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-005985-35\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-005985-35\/CZ\">CZ<\/a> (Prematurely Ended)<\/p>","65":"<p>EudraCT Number: 2016-004935-18<br \/>Sponsor Protocol Number: GNC-004<br \/>Sponsor Name: GeNeuro SA<br \/>Start Date: 2017-04-12<br \/>Medical condition: Multiple Sclerosis (MS)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/HU\">HU<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/CZ\">CZ<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/PL\">PL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/BG\">BG<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/HR\">HR<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-004935-18\/IT\">IT<\/a> (Completed)<\/p>","66":"<p>EudraCT Number: 2013-004450-21<br \/>Sponsor Protocol Number: EMR200136-570<br \/>Sponsor Name: Merck Serono S.p.A.<br \/>Start Date: 2014-02-07<br \/>Medical condition: relapsing multiple sclerosis<br \/>Disease: <br \/>Version: 14.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004450-21\/IT\">IT<\/a> (Completed)<\/p>","67":"<p>EudraCT Number: 2013-002112-27<br \/>Sponsor Protocol Number: MD1003CT2013-01MS-ON<br \/>Sponsor Name: MEDDAY SAS<br \/>Start Date: Information not available in EudraCT<br \/>Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis<br \/>Disease: <br \/>Version: 18.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 18.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10030942<br \/>Term: Optic neuritis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002112-27\/FR\">FR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002112-27\/GB\">GB<\/a> (GB - no longer in EU\/EEA)<\/p>","68":"<p>EudraCT Number: 2004-000337-12<br \/>Sponsor Protocol Number: 24810<br \/>Sponsor Name: Serono International SA<br \/>Start Date: 2004-07-23<br \/>Medical condition: MS with 2 or more relapses within the last 2 years <br \/>Disease: <br \/>Version: 7.0<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: <br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-000337-12\/HU\">HU<\/a> (Completed)<\/p>","69":"<p>EudraCT Number: 2009-014857-34<br \/>Sponsor Protocol Number: FAU-001<br \/>Sponsor Name: Universit\u00e4tsklinikum Erlangen<br \/>Start Date: 2010-02-01<br \/>Medical condition: Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald\u2019s criteria<br \/>Disease: <br \/>Version: 12.0<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-014857-34\/DE\">DE<\/a> (Completed)<\/p>","70":"<p>EudraCT Number: 2004-000762-13<br \/>Sponsor Protocol Number: TV-5010\/202<br \/>Sponsor Name: TEVA ITALIA srl<br \/>Start Date: 2004-08-31<br \/>Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit.<br \/>Disease: <br \/>Version: 15.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-000762-13\/IT\">IT<\/a> (Completed)<\/p>","71":"<b>Condition<\/b>: \u00a0  Relapsing-Remitting\u00a0Multiple\u00a0Sclerosis\u00a0(RRMS)<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Natalizumab<br \/><b>Sponsor<\/b>: \u00a0  Biogen<br \/><b>Recruiting<\/b>","72":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  <br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Recruiting<\/b>","73":"<p>EudraCT Number: 2007-001377-28<br \/>Sponsor Protocol Number: 27577<br \/>Sponsor Name: Merck Serono International S.A.<br \/>Start Date: 2008-06-11<br \/>Medical condition: Adult patients with moderate to severe chronic plaque psoriasis \n-- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10061664<br \/>Term: Autoimmune disorder<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10025139<br \/>Term: Lupus erythematosus systemic<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10047888<br \/>Term: Wegener's granulomatosis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10002817<br \/>Term: Antiphospholipid syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10040767<br \/>Term: Sjogren's syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10039073<br \/>Term: Rheumatoid arthritis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10045228<br \/>Term: Type I diabetes mellitus<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10011401<br \/>Term: Crohn's disease<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10009900<br \/>Term: Colitis ulcerative<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10003827<br \/>Term: Autoimmune hepatitis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10049046<br \/>Term: Autoimmune thyroiditis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10003822<br \/>Term: Autoimmune haemolytic anaemia NOS<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10034697<br \/>Term: Pernicious anemia<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028417<br \/>Term: Myasthenia gravis<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10018620<br \/>Term: Goodpasture's syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10018766<br \/>Term: Guillain Barre syndrome<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10043554<br \/>Term: Thrombocytopenia<br \/>Level: LLT<br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10037153<br \/>Term: Psoriasis<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/FR\">FR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/NL\">NL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001377-28\/PT\">PT<\/a> (Prematurely Ended)<\/p>","74":"<p>EudraCT Number: 2019-001341-40<br \/>Sponsor Protocol Number: COMB157G23101<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2020-05-07<br \/>Medical condition: Multiple sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001341-40\/LV\">LV<\/a> (Ongoing)<\/p>","75":"<p>EudraCT Number: 2010-020338-25<br \/>Sponsor Protocol Number: WA25046<br \/>Sponsor Name: F.Hoffmann-La Roche<br \/>Start Date: 2010-11-02<br \/>Medical condition: Primary Progressive Multiple Sclerosis (PPMS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/FI\">FI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/BG\">BG<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/DK\">DK<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020338-25\/PL\">PL<\/a> (Ongoing)<\/p>","76":"<p>EudraCT Number: 2020-005448-48<br \/>Sponsor Protocol Number: CN42097<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2022-03-15<br \/>Medical condition: Multiple Sclerosis (MS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063401<br \/>Term: Primary progressive multiple sclerosis<br \/>Level: PT<br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-005448-48\/IT\">IT<\/a> (Ongoing)<\/p>","77":"<p>EudraCT Number: 2006-004784-58<br \/>Sponsor Protocol Number: MRI-0143<br \/>Sponsor Name: University of Leuven<br \/>Start Date: 2007-06-22<br \/>Medical condition: Crohn's disease<br \/>Disease: <br \/>Version: 8.1<br \/>SOC Term: <br \/>Classification Code: 10011401<br \/>Term: Crohn's disease<br \/>Level: LLT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004784-58\/GB\">GB<\/a> (Prematurely Ended)<\/p>","78":"<p>EudraCT Number: 2007-005994-79<br \/>Sponsor Protocol Number: 3133K1-3000-WW<br \/>Sponsor Name: Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development<br \/>Start Date: 2008-05-13<br \/>Medical condition: Enfermedad de Alzheimer\n\nAlzheimer Disease<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10012271<br \/>Term: Dementia Alzheimer's type<br \/>Level: PT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/IE\">IE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/GB\">GB<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/DE\">DE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/FI\">FI<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/SE\">SE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/IT\">IT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/PT\">PT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/AT\">AT<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/NL\">NL<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005994-79\/DK\">DK<\/a> (Prematurely Ended)<\/p>","79":"<p>EudraCT Number: 2020-000579-19<br \/>Sponsor Protocol Number: MAGNET<br \/>Sponsor Name: Stichting TRICALS Foundation<br \/>Start Date: 2021-06-25<br \/>Medical condition: Amyotrophic Lateral Sclerosis<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000579-19\/NL\">NL<\/a> (Ongoing)<\/p>","80":"<p>EudraCT Number: 2020-004505-32<br \/>Sponsor Protocol Number: COMB157G3301<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2021-06-09<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004505-32\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004505-32\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004505-32\/IT\">IT<\/a> (Ongoing)<\/p>","81":"<p>EudraCT Number: 2020-001168-28<br \/>Sponsor Protocol Number: GN42272<br \/>Sponsor Name: F. Hoffman-La Roche<br \/>Start Date: 2021-03-01<br \/>Medical condition: Relapsing multiple sclerosis (RMS)<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 21.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10080700<br \/>Term: Relapsing multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001168-28\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001168-28\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001168-28\/IT\">IT<\/a> (Ongoing)<\/p>","82":"<p>EudraCT Number: 2005-001540-23<br \/>Sponsor Protocol Number: 309560<br \/>Sponsor Name: Schering Nordiska AB<br \/>Start Date: 2006-03-03<br \/>Medical condition: Early Secondary Progressive Multiple Sclerosis<br \/>Disease: <br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001540-23\/SE\">SE<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001540-23\/DK\">DK<\/a> (Completed)<\/p>","83":"<p>EudraCT Number: 2012-005076-34<br \/>Sponsor Protocol Number: BEL-FMP-12-10325<br \/>Sponsor Name: Cliniques Universitaires Saint-Luc, Neurologie<br \/>Start Date: 2013-01-03<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005076-34\/BE\">BE<\/a> (Completed)<\/p>","84":"<p>EudraCT Number: 2017-004886-29<br \/>Sponsor Protocol Number: MN39158<br \/>Sponsor Name: Roche Farma SA (Soc unipersonal) que realiza el ensayo en Espa\u00f1a y que act\u00faa como representante F.Hoffmann-La Roche Ltd<br \/>Start Date: 2018-05-22<br \/>Medical condition: Multiple sclerosis (MS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/ES\">ES<\/a> (Prematurely Ended), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/IE\">IE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/FI\">FI<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004886-29\/HR\">HR<\/a> (Ongoing)<\/p>","85":"<p>EudraCT Number: 2020-000893-69<br \/>Sponsor Protocol Number: BN42082<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2020-10-28<br \/>Medical condition: Relapsing Multiple Sclerosis (MS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10039720<br \/>Term: Sclerosis multiple<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/GB\">GB<\/a> (GB - no longer in EU\/EEA), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/NL\">NL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000893-69\/IT\">IT<\/a> (Ongoing)<\/p>","86":"<p>EudraCT Number: 2017-001362-25<br \/>Sponsor Protocol Number: RAM-MS<br \/>Sponsor Name: Helse Bergen HF, Haukeland University Hospital<br \/>Start Date: 2018-05-02<br \/>Medical condition: Relapsing remitting multiple sclerosis.<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001362-25\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001362-25\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001362-25\/NL\">NL<\/a> (Ongoing)<\/p>","87":"<p>EudraCT Number: 2015-002500-91<br \/>Sponsor Protocol Number: RPC01-3001<br \/>Sponsor Name: Celgene International II S\u00e0rl (CIS II)<br \/>Start Date: 2015-10-12<br \/>Medical condition: Relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/GB\">GB<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/SE\">SE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/HR\">HR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-002500-91\/IT\">IT<\/a> (Ongoing)<\/p>","88":"<p>EudraCT Number: 2019-004980-36<br \/>Sponsor Protocol Number: MS200527-0082<br \/>Sponsor Name: Merck Healthcare KGaA<br \/>Start Date: 2020-09-21<br \/>Medical condition: Relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10048393<br \/>Term: Multiple sclerosis relapse<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/GR\">GR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/BG\">BG<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/NO\">NO<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/SI\">SI<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-004980-36\/IT\">IT<\/a> (Ongoing)<\/p>","89":"<p>EudraCT Number: 2019-000069-19<br \/>Sponsor Protocol Number: MS700568_0026<br \/>Sponsor Name: Merck KGaA<br \/>Start Date: 2019-07-12<br \/>Medical condition: Multiple Sclerosis<br \/>Disease: <br \/>Version: 20.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10029205<br \/>Term: Nervous system disorders<br \/>Level: SOC<br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/SE\">SE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/PT\">PT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/EE\">EE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/BG\">BG<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/AT\">AT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/LT\">LT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/HR\">HR<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000069-19\/RO\">RO<\/a> (Completed)<\/p>","90":"<p>EudraCT Number: 2013-003884-71<br \/>Sponsor Protocol Number: LPS13649<br \/>Sponsor Name: Genzyme Corporation<br \/>Start Date: 2015-02-05<br \/>Medical condition: Relapsing-remitting multiple sclerosis<br \/>Disease: <br \/>Version: 17.0<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/NL\">NL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/CZ\">CZ<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/IT\">IT<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/DK\">DK<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-003884-71\/HR\">HR<\/a> (Completed)<\/p>","91":"<p>EudraCT Number: 2020-002700-39<br \/>Sponsor Protocol Number: CBAF312D2301<br \/>Sponsor Name: Novartis Pharma AG<br \/>Start Date: 2021-09-10<br \/>Medical condition: Multiple Sclerosis in pediatric patients<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Children, Adolescents, Under 18<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/DE\">DE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/PT\">PT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/EE\">EE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/FR\">FR<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/BE\">BE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/LT\">LT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/AT\">AT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/SK\">SK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/LV\">LV<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002700-39\/HR\">HR<\/a> (Ongoing)<\/p>","92":"<p>EudraCT Number: 2015-005160-41<br \/>Sponsor Protocol Number: ALK8700-A301<br \/>Sponsor Name: Biogen Idec Research Limited<br \/>Start Date: 2016-07-27<br \/>Medical condition: Relapsing Remitting Multiple Sclerosis<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults, Elderly<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/DE\">DE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/BE\">BE<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/ES\">ES<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005160-41\/BG\">BG<\/a> (Completed)<\/p>","93":"<p>EudraCT Number: 2018-004751-20<br \/>Sponsor Protocol Number: PB006-03-01<br \/>Sponsor Name: Polpharma Biologics S.A.<br \/>Start Date: 2019-07-22<br \/>Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)<br \/>Disease: <br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10063399<br \/>Term: Relapsing-remitting multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004751-20\/PL\">PL<\/a> (Completed), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004751-20\/HR\">HR<\/a> (Completed)<\/p>","94":"<p>EudraCT Number: 2017-001313-93<br \/>Sponsor Protocol Number: MN39159<br \/>Sponsor Name: F. Hoffmann-La Roche Ltd<br \/>Start Date: 2018-05-03<br \/>Medical condition: Progressive multiple sclerosis (PMS)<br \/>Disease: <br \/>Version: 20.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: PT<br \/>Version: 21.1<br \/>SOC Term: 10029205 - Nervous system disorders<br \/>Classification Code: 10053395<br \/>Term: Progressive multiple sclerosis<br \/>Level: PT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/IE\">IE<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/DK\">DK<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/ES\">ES<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/PL\">PL<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/CZ\">CZ<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/HU\">HU<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/IT\">IT<\/a> (Ongoing), <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001313-93\/DE\">DE<\/a> (Ongoing)<\/p>","95":"<p>EudraCT Number: 2008-003098-42<br \/>Sponsor Protocol Number: 108MS303<br \/>Sponsor Name: Biogen Idec Ltd<br \/>Start Date: 2009-01-06<br \/>Medical condition: To evaluate the immunogenicity of Avonex\u00ae 30 mcg when administered SC to interferon-na\u00efve subjects with relapsing Multiple Sclerosis<br \/>Disease: <br \/>Version: 9.1<br \/>SOC Term: <br \/>Classification Code: 10028245<br \/>Term: Multiple sclerosis<br \/>Level: LLT<br \/><br \/>Population Age: Adults<br \/>Gender: Male, Female<br \/>Trial Protocol: <a href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-003098-42\/CZ\">CZ<\/a> (Completed)<\/p>","96":"<b>Conditions<\/b>: \u00a0  Systemic\u00a0Sclerosis; \u00a0 Multisystem\u00a0Disorder<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0MRI<br \/><b>Sponsors<\/b>: \u00a0  Tsinghua\u00a0University; \u00a0 Peking\u00a0Union\u00a0Medical\u00a0College\u00a0Hospital<br \/><b>Recruiting<\/b>","97":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 3D\u00a0Gait\u00a0Analysis; \u00a0 Vestibular\u00a0Rehabilitation<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Vestibular\u00a0exercises; \u00a0 Other:\u00a0Standard\u00a0neurorehabilitation\u00a0exercises<br \/><b>Sponsors<\/b>: \u00a0  Istanbul\u00a0K\u00fclt\u00fcr\u00a0University; \u00a0 Istanbul\u00a0University-Cerrahpasa<br \/><b>Not yet recruiting<\/b>","98":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug: Metformin 1000 mg (Cidophage\u00ae 1000 mg tablets, CID, Giza, Egypt) tablet; \u00a0 Drug:\u00a0Interferon\u00a0beta-1a<br \/><b>Sponsor<\/b>: \u00a0  German\u00a0University\u00a0in\u00a0Cairo<br \/><b>Not yet recruiting<\/b>","99":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Ocrelizumab<br \/><b>Sponsor<\/b>: \u00a0  VU\u00a0University\u00a0Medical\u00a0Center<br \/><b>Not yet recruiting<\/b>","100":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Stroke; \u00a0 Cystic\u00a0Fibrosis; \u00a0 Motor\u00a0Neurone\u00a0Disease; \u00a0 Craniocerebral\u00a0Trauma; \u00a0 Guillain-Barre\u00a0Syndrome<br \/><b>Intervention<\/b>: \u00a0  Device: Powered Wheelchair Obstacle Alerting System<br \/><b>Sponsors<\/b>: \u00a0  East Kent Hospitals University NHS Foundation Trust; \u00a0 University\u00a0of\u00a0Kent; \u00a0 Sussex\u00a0Community\u00a0NHS\u00a0Foundation\u00a0Trust; \u00a0 KU\u00a0Leuven; \u00a0 l'Institut sup\u00e9rieur de l'\u00e9lectronique et du num\u00e9rique (ISEN) Lille<br \/><b>Completed<\/b>","101":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  Genetic:\u00a050\u00a0ml\u00a0blodd\u00a0sampling<br \/><b>Sponsors<\/b>: \u00a0  Institut\u00a0Pasteur; \u00a0 H\u00f6pital\u00a0La\u00a0Piti\u00e9-Salp\u00eatri\u00e8re<br \/><b>Not yet recruiting<\/b>","102":"<b>Condition<\/b>: \u00a0  Amyotrophic\u00a0Lateral\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0prosetin; \u00a0 Drug:\u00a0placebo<br \/><b>Sponsors<\/b>: \u00a0  ProJenX; \u00a0 Worldwide\u00a0Clinical\u00a0Trials<br \/><b>Recruiting<\/b>","103":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Autoimmune\u00a0Blistering\u00a0Disease; \u00a0 B-Cell\u00a0Deficiency<br \/><b>Intervention<\/b>: \u00a0  Biological:\u00a0COVID19\u00a0vaccine<br \/><b>Sponsors<\/b>: \u00a0  Yale\u00a0University; \u00a0 National Institute of Allergy and Infectious Diseases (NIAID); \u00a0 Robert\u00a0Leet\u00a0and\u00a0Clara\u00a0Guthrie\u00a0Patterson\u00a0Trust<br \/><b>Active, not recruiting<\/b>","104":"<b>Conditions<\/b>: \u00a0  Clinically\u00a0Isolated\u00a0Syndrome; \u00a0 Relapsing\u00a0Remitting\u00a0Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Device:\u00a0Eye-tracking<br \/><b>Sponsors<\/b>: \u00a0  McGill\u00a0University; \u00a0 Innodem\u00a0Neurosciences<br \/><b>Not yet recruiting<\/b>","105":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Famciclovir<br \/><b>Sponsor<\/b>: \u00a0  Queen\u00a0Mary\u00a0University\u00a0of\u00a0London<br \/><b>Recruiting<\/b>","106":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0Ofatumumab<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","107":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Biological:\u00a0Ocrelizumab; \u00a0 Drug:\u00a0Placebo\u00a0for\u00a0Ocrelizumab<br \/><b>Sponsors<\/b>: \u00a0  National Institute of Allergy and Infectious Diseases (NIAID); \u00a0 Autoimmunity\u00a0Centers\u00a0of\u00a0Excellence\u00a0(ACE)<br \/><b>Not yet recruiting<\/b>","108":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Combination Product: PT plus translingual stimulation device; \u00a0 Combination Product: PT plus translingual stimulation control device<br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Saskatchewan; \u00a0 Memorial\u00a0University\u00a0of\u00a0Newfoundland<br \/><b>Enrolling by invitation<\/b>","109":"<b>Conditions<\/b>: \u00a0  Multiple\u00a0Sclerosis; \u00a0 Sleep; \u00a0 Pain<br \/><b>Interventions<\/b>: \u00a0  Drug:\u00a0Cannabidiol\u00a0(CBD); \u00a0 Drug:\u00a0Tetrahydrocannabinol\u00a0(THC); \u00a0 Drug:\u00a0Placebo\u00a0CBD; \u00a0 Drug:\u00a0Placebo\u00a0THC<br \/><b>Sponsors<\/b>: \u00a0  Tiffany\u00a0J.\u00a0Braley,\u00a0MD,\u00a0MS; \u00a0 National Center for Complementary and Integrative Health (NCCIH)<br \/><b>Not yet recruiting<\/b>","110":"<b>Condition<\/b>: \u00a0  Relapsing\u00a0Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Ofatumumab; \u00a0 Other:\u00a0Ocrelizumab<br \/><b>Sponsor<\/b>: \u00a0  Novartis\u00a0Pharmaceuticals<br \/><b>Not yet recruiting<\/b>","111":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis,\u00a0Relapsing-Remitting<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Natalizumab<br \/><b>Sponsor<\/b>: \u00a0  Biogen<br \/><b>Not yet recruiting<\/b>","112":"<b>Condition<\/b>: \u00a0  Children\u00a0With\u00a0Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Other:\u00a0MRI\u00a0without\u00a0injection\u00a0of\u00a0contrast\u00a0product<br \/><b>Sponsor<\/b>: \u00a0  Assistance\u00a0Publique\u00a0-\u00a0H\u00f4pitaux\u00a0de\u00a0Paris<br \/><b>Not yet recruiting<\/b>","113":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  Drug:\u00a0Ocrelizumab<br \/><b>Sponsor<\/b>: \u00a0  Hoffmann-La\u00a0Roche<br \/><b>Not yet recruiting<\/b>","114":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Intervention<\/b>: \u00a0  <br \/><b>Sponsors<\/b>: \u00a0  University\u00a0of\u00a0Michigan; \u00a0 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); \u00a0 Wayne\u00a0State\u00a0University; \u00a0 University\u00a0of\u00a0Washington<br \/><b>Not yet recruiting<\/b>","115":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Other:\u00a0Blood\u00a0Test\u00a01; \u00a0 Other:\u00a0Blood\u00a0Test\u00a02<br \/><b>Sponsor<\/b>: \u00a0  University\u00a0Hospitals\u00a0of\u00a0North\u00a0Midlands\u00a0NHS\u00a0Trust<br \/><b>Recruiting<\/b>","116":"<b>Condition<\/b>: \u00a0  Multiple\u00a0Sclerosis<br \/><b>Interventions<\/b>: \u00a0  Behavioral:\u00a0N-back\u00a0Cognitive\u00a0Training; \u00a0 Behavioral: Virtual Reality Motor and Cognitive Training<br \/><b>Sponsor<\/b>: \u00a0  Universitat\u00a0Jaume\u00a0I<br \/><b>Recruiting<\/b>"},"link":{"0":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05347277?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","1":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05349474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","2":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-002901-37","3":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05345288?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","4":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05344040?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","5":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05344469?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","6":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-003752-21","7":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000028-36","8":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000307-20","9":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000637-41","10":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-005249-12","11":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05340985?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","12":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05341895?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","13":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05332951?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","14":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05335031?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","15":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05338450?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","16":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05342025?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","17":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05334472?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","18":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04946318","19":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04575025","20":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04058067","21":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04812548","22":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct05114746","23":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04926818","24":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04632056","25":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04781881","26":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04795427","27":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04679935","28":"https:\/\/www.novartis.com\/","29":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04795466","30":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04940065","31":"https:\/\/www.novartis.com\/","32":"https:\/\/www.novartis.com\/\/clinicaltrials\/study\/nct04868968","33":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05327322?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","34":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05326711?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","35":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05326048?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","36":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05325359?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","37":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05321927?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","38":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05322915?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","39":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05320237?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","40":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-000638-75","41":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-000639-15","42":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-000001-23","43":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2016-002937-31","44":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05319093?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","45":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000639-30","46":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-000606-23","47":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05313204?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","48":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-005929-89","49":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-001197-18","50":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-004822-15","51":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-000048-23","52":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2014-001579-30","53":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-004557-24","54":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05312138?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","55":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-006299-39","56":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2010-018273-38","57":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-011088-35","58":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2011-001437-16","59":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000645-14","60":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-002113-35","61":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-000392-28","62":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-004061-41","63":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000647-30","64":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-005985-35","65":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2016-004935-18","66":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-004450-21","67":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-002112-27","68":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-000337-12","69":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2009-014857-34","70":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-000762-13","71":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05304520?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","72":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05301907?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","73":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-001377-28","74":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-001341-40","75":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2010-020338-25","76":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-005448-48","77":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-004784-58","78":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-005994-79","79":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000579-19","80":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-004505-32","81":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-001168-28","82":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2005-001540-23","83":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-005076-34","84":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-004886-29","85":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-000893-69","86":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-001362-25","87":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-002500-91","88":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-004980-36","89":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2019-000069-19","90":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-003884-71","91":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-002700-39","92":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2015-005160-41","93":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-004751-20","94":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-001313-93","95":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-003098-42","96":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05297474?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","97":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05299151?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","98":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05298670?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","99":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05296161?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","100":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05292690?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","101":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05290688?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","102":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05279755?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","103":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05286242?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","104":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05277740?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","105":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05283551?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","106":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05285904?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","107":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05285891?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","108":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05275049?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","109":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269628?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","110":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05266469?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","111":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05265728?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","112":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05258396?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","113":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269004?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","114":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05252195?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","115":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05269888?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14","116":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05270239?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14"},"published_date":{"0":1650988800000,"1":1651075200000,"2":null,"3":1650902400000,"4":1650902400000,"5":1650902400000,"6":null,"7":null,"8":null,"9":null,"10":null,"11":1650643200000,"12":1650643200000,"13":1650297600000,"14":1650384000000,"15":1650556800000,"16":1650643200000,"17":1650384000000,"18":null,"19":null,"20":null,"21":null,"22":null,"23":null,"24":null,"25":null,"26":null,"27":null,"28":null,"29":null,"30":null,"31":null,"32":null,"33":1649952000000,"34":1649865600000,"35":1649865600000,"36":1649865600000,"37":1649692800000,"38":1649779200000,"39":1649692800000,"40":null,"41":null,"42":null,"43":null,"44":1649433600000,"45":null,"46":null,"47":1649260800000,"48":null,"49":null,"50":null,"51":null,"52":null,"53":null,"54":1649174400000,"55":null,"56":null,"57":null,"58":null,"59":null,"60":null,"61":null,"62":null,"63":null,"64":null,"65":null,"66":null,"67":null,"68":null,"69":null,"70":null,"71":1648742400000,"72":1648742400000,"73":null,"74":null,"75":null,"76":null,"77":null,"78":null,"79":null,"80":null,"81":null,"82":null,"83":null,"84":null,"85":null,"86":null,"87":null,"88":null,"89":null,"90":null,"91":null,"92":null,"93":null,"94":null,"95":null,"96":1648483200000,"97":1648483200000,"98":1648483200000,"99":1648224000000,"100":1648051200000,"101":1647964800000,"102":1647360000000,"103":1647619200000,"104":1647273600000,"105":1647532800000,"106":1647619200000,"107":1647619200000,"108":1647018000000,"109":1646758800000,"110":1646413200000,"111":1646326800000,"112":1646067600000,"113":1646672400000,"114":1645635600000,"115":1646758800000,"116":1646758800000},"source":{"0":12,"1":12,"2":16,"3":12,"4":12,"5":12,"6":16,"7":16,"8":16,"9":16,"10":16,"11":12,"12":12,"13":12,"14":12,"15":12,"16":12,"17":12,"18":13,"19":13,"20":13,"21":13,"22":13,"23":13,"24":13,"25":13,"26":13,"27":13,"28":13,"29":13,"30":13,"31":13,"32":13,"33":12,"34":12,"35":12,"36":12,"37":12,"38":12,"39":12,"40":16,"41":16,"42":16,"43":16,"44":12,"45":16,"46":16,"47":12,"48":16,"49":16,"50":16,"51":16,"52":16,"53":16,"54":12,"55":16,"56":16,"57":16,"58":16,"59":16,"60":16,"61":16,"62":16,"63":16,"64":16,"65":16,"66":16,"67":16,"68":16,"69":16,"70":16,"71":12,"72":12,"73":16,"74":16,"75":16,"76":16,"77":16,"78":16,"79":16,"80":16,"81":16,"82":16,"83":16,"84":16,"85":16,"86":16,"87":16,"88":16,"89":16,"90":16,"91":16,"92":16,"93":16,"94":16,"95":16,"96":12,"97":12,"98":12,"99":12,"100":12,"101":12,"102":12,"103":12,"104":12,"105":12,"106":12,"107":12,"108":12,"109":12,"110":12,"111":12,"112":12,"113":12,"114":12,"115":12,"116":12},"relevant":{"0":"","1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":"","9":"","10":"","11":"","12":"","13":"","14":"","15":"","16":"","17":"","18":"","19":"","20":"","21":"","22":"","23":"","24":"","25":"","26":"","27":"","28":"","29":"","30":"","31":"","32":"","33":"","34":"","35":"","36":"","37":"","38":"","39":"","40":"","41":"","42":"","43":"","44":"","45":"","46":"","47":"","48":"","49":"","50":"","51":"","52":"","53":"","54":"","55":"","56":"","57":"","58":"","59":"","60":"","61":"","62":"","63":"","64":"","65":"","66":"","67":"","68":"","69":"","70":"","71":"","72":"","73":"","74":"","75":"","76":"","77":"","78":"","79":"","80":"","81":"","82":"","83":"","84":"","85":"","86":"","87":"","88":"","89":"","90":"","91":"","92":"","93":"","94":"","95":"","96":"","97":"","98":"","99":"","100":"","101":"","102":"","103":"","104":"","105":"","106":"","107":"","108":"","109":"","110":"","111":"","112":"","113":"","114":"","115":"","116":""},"Sources__source_id":{"0":12,"1":12,"2":16,"3":12,"4":12,"5":12,"6":16,"7":16,"8":16,"9":16,"10":16,"11":12,"12":12,"13":12,"14":12,"15":12,"16":12,"17":12,"18":13,"19":13,"20":13,"21":13,"22":13,"23":13,"24":13,"25":13,"26":13,"27":13,"28":13,"29":13,"30":13,"31":13,"32":13,"33":12,"34":12,"35":12,"36":12,"37":12,"38":12,"39":12,"40":16,"41":16,"42":16,"43":16,"44":12,"45":16,"46":16,"47":12,"48":16,"49":16,"50":16,"51":16,"52":16,"53":16,"54":12,"55":16,"56":16,"57":16,"58":16,"59":16,"60":16,"61":16,"62":16,"63":16,"64":16,"65":16,"66":16,"67":16,"68":16,"69":16,"70":16,"71":12,"72":12,"73":16,"74":16,"75":16,"76":16,"77":16,"78":16,"79":16,"80":16,"81":16,"82":16,"83":16,"84":16,"85":16,"86":16,"87":16,"88":16,"89":16,"90":16,"91":16,"92":16,"93":16,"94":16,"95":16,"96":12,"97":12,"98":12,"99":12,"100":12,"101":12,"102":12,"103":12,"104":12,"105":12,"106":12,"107":12,"108":12,"109":12,"110":12,"111":12,"112":12,"113":12,"114":12,"115":12,"116":12},"Sources__name":{"0":"ClinicalTrials.gov","1":"ClinicalTrials.gov","2":"Clinical Trials Register Europe","3":"ClinicalTrials.gov","4":"ClinicalTrials.gov","5":"ClinicalTrials.gov","6":"Clinical Trials Register Europe","7":"Clinical Trials Register Europe","8":"Clinical Trials Register Europe","9":"Clinical Trials Register Europe","10":"Clinical Trials Register Europe","11":"ClinicalTrials.gov","12":"ClinicalTrials.gov","13":"ClinicalTrials.gov","14":"ClinicalTrials.gov","15":"ClinicalTrials.gov","16":"ClinicalTrials.gov","17":"ClinicalTrials.gov","18":"Novartis","19":"Novartis","20":"Novartis","21":"Novartis","22":"Novartis","23":"Novartis","24":"Novartis","25":"Novartis","26":"Novartis","27":"Novartis","28":"Novartis","29":"Novartis","30":"Novartis","31":"Novartis","32":"Novartis","33":"ClinicalTrials.gov","34":"ClinicalTrials.gov","35":"ClinicalTrials.gov","36":"ClinicalTrials.gov","37":"ClinicalTrials.gov","38":"ClinicalTrials.gov","39":"ClinicalTrials.gov","40":"Clinical Trials Register Europe","41":"Clinical Trials Register Europe","42":"Clinical Trials Register Europe","43":"Clinical Trials Register Europe","44":"ClinicalTrials.gov","45":"Clinical Trials Register Europe","46":"Clinical Trials Register Europe","47":"ClinicalTrials.gov","48":"Clinical Trials Register Europe","49":"Clinical Trials Register Europe","50":"Clinical Trials Register Europe","51":"Clinical Trials Register Europe","52":"Clinical Trials Register Europe","53":"Clinical Trials Register Europe","54":"ClinicalTrials.gov","55":"Clinical Trials Register Europe","56":"Clinical Trials Register Europe","57":"Clinical Trials Register Europe","58":"Clinical Trials Register Europe","59":"Clinical Trials Register Europe","60":"Clinical Trials Register Europe","61":"Clinical Trials Register Europe","62":"Clinical Trials Register Europe","63":"Clinical Trials Register Europe","64":"Clinical Trials Register Europe","65":"Clinical Trials Register Europe","66":"Clinical Trials Register Europe","67":"Clinical Trials Register Europe","68":"Clinical Trials Register Europe","69":"Clinical Trials Register Europe","70":"Clinical Trials Register Europe","71":"ClinicalTrials.gov","72":"ClinicalTrials.gov","73":"Clinical Trials Register Europe","74":"Clinical Trials Register Europe","75":"Clinical Trials Register Europe","76":"Clinical Trials Register Europe","77":"Clinical Trials Register Europe","78":"Clinical Trials Register Europe","79":"Clinical Trials Register Europe","80":"Clinical Trials Register Europe","81":"Clinical Trials Register Europe","82":"Clinical Trials Register Europe","83":"Clinical Trials Register Europe","84":"Clinical Trials Register Europe","85":"Clinical Trials Register Europe","86":"Clinical Trials Register Europe","87":"Clinical Trials Register Europe","88":"Clinical Trials Register Europe","89":"Clinical Trials Register Europe","90":"Clinical Trials Register Europe","91":"Clinical Trials Register Europe","92":"Clinical Trials Register Europe","93":"Clinical Trials Register Europe","94":"Clinical Trials Register Europe","95":"Clinical Trials Register Europe","96":"ClinicalTrials.gov","97":"ClinicalTrials.gov","98":"ClinicalTrials.gov","99":"ClinicalTrials.gov","100":"ClinicalTrials.gov","101":"ClinicalTrials.gov","102":"ClinicalTrials.gov","103":"ClinicalTrials.gov","104":"ClinicalTrials.gov","105":"ClinicalTrials.gov","106":"ClinicalTrials.gov","107":"ClinicalTrials.gov","108":"ClinicalTrials.gov","109":"ClinicalTrials.gov","110":"ClinicalTrials.gov","111":"ClinicalTrials.gov","112":"ClinicalTrials.gov","113":"ClinicalTrials.gov","114":"ClinicalTrials.gov","115":"ClinicalTrials.gov","116":"ClinicalTrials.gov"},"Sources__link":{"0":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","1":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","2":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","3":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","4":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","5":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","6":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","7":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","8":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","9":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","10":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","11":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","12":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","13":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","14":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","15":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","16":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","17":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","18":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","19":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","20":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","21":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","22":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","23":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","24":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","25":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","26":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","27":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","28":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","29":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","30":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","31":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","32":"https:\/\/www.recruiting-trials.novartis.com\/?condition=1691&phase=All","33":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","34":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","35":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","36":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","37":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","38":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","39":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","40":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","41":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","42":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","43":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","44":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","45":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","46":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","47":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","48":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","49":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","50":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","51":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","52":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","53":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","54":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","55":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","56":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","57":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","58":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","59":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","60":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","61":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","62":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","63":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","64":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","65":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","66":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","67":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","68":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","69":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","70":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","71":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","72":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","73":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","74":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","75":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","76":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","77":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","78":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","79":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","80":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","81":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","82":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","83":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","84":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","85":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","86":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","87":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","88":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","89":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","90":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","91":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","92":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","93":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","94":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","95":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/feed\/bydates?query=multiple+sclerosis","96":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","97":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","98":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","99":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","100":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","101":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","102":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","103":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","104":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","105":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","106":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","107":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","108":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","109":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","110":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","111":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","112":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","113":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","114":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","115":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000","116":"https:\/\/clinicaltrials.gov\/ct2\/results\/rss.xml?rcv_d=14&lup_d=&sel_rss=new14&cond=Multiple+Sclerosis&count=10000"}}